{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:30:15Z","timestamp":1748302215756,"version":"3.40.5"},"reference-count":9,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is no currently available standard of care for triple\u2010class exposed, relapsed refractory myeloma (RRMM) patients in Australia. CARTITUDE\u20101 (CART\u20101) was a single\u2010arm, phase 1b\/2 study of 97 triple\u2010class exposed RRMM patients, who received BCMA\u2010CAR\u2010T cell therapy with ciltacabtagene autocel. Overall response rate (ORR) was 98%. Median progression free survival (PFS) and overall survival (OS) had not been reached at a median follow\u2010up of 28 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective analysis on a cohort of CART\u20101 comparable RRMM patients participating in the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR), to compare outcomes in triple\u2010class exposed MM patients treated with currently available therapies, in a real\u2010world context. The CE\u2010MRDR cohort (<jats:italic>n<\/jats:italic> =\u200928) fulfilled CARTITUDE\u20101 eligibility (CE) criteria: \u22653 lines of therapy (LOT) including an immunomodulatory agent, proteasome inhibitor and CD38\u2010directed monoclonal antibody (CD38mAb) and Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0\u20132 at diagnosis. The modified\u2010CE\u2010MRDR (<jats:italic>n<\/jats:italic> =\u2009132) received \u22653 LOT but may not have received a CD38mAb with an ECOG PS score of 3 (0\u20133).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Responses to the first subsequent therapy after eligibility were poor \u2013 ORR was 23% and 0% with progressive disease (PD) reported in 61% and 36%, CE\u2010MRDR and m\u2010CE\u2010MRDR respectively. Responses to the second subsequent therapy after eligibility were worse, ORR 0% and 31%, CE\u2010MRDR and m\u2010CE\u2010MRDR respectively, with high rates of PD, particularly in CE\u2010MRDR. Median OS was 5.4 versus 9.5 months, CE\u2010MRDR versus m\u2010CE\u2010MRDR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This retrospective analysis confirms uniformly poor outcomes for Australian RRMM patients. There remains a critical need for greater accessibility to novel treatments, such as CAR\u2010T, outside clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.16277","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T09:05:16Z","timestamp":1703667916000},"page":"773-778","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real\u2010world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the <scp>ANZ<\/scp> myeloma and related diseases registry"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-8832","authenticated-orcid":false,"given":"Sueh\u2010li","family":"Lim","sequence":"first","affiliation":[{"name":"Clinical and Translational Myeloma Alfred Health  Melbourne Victoria Australia"},{"name":"Australian Centre for Blood Diseases Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-6000","authenticated-orcid":false,"given":"Elizabeth","family":"Moore","sequence":"additional","affiliation":[{"name":"Public Health and Preventive Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quach","family":"Hang","sequence":"additional","affiliation":[{"name":"St. Vincent's Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Ho","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital  Camperdown New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Middlemore Hospital  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"Australian Centre for Blood Diseases Monash University  Melbourne Victoria Australia"},{"name":"Head, Malignant Haematology &amp; Stem Cell Transplantation Services Alfred Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.312"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1953456"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0711-6"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T02:06:57Z","timestamp":1715911617000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/imj.16277"],"URL":"https:\/\/doi.org\/10.1111\/imj.16277","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"type":"print","value":"1444-0903"},{"type":"electronic","value":"1445-5994"}],"subject":[],"published":{"date-parts":[[2023,12,27]]},"assertion":[{"value":"2023-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}